東誠藥業(002675.SZ):意向投資分子影像CRO企業米度生物
格隆匯5月25日丨東誠藥業(002675.SZ)宣佈,2020年5月24日,公司全資子公司安迪科和/或其關聯方作為投資人與米度生物及其股東世康控股、南京米安北、南京雲米簽署了《關於米度(南京)生物技術有限公司投資意向書》,投資人擬通過增資及收購世康控股所持米度生物48.31%股權的方式投資米度生物。投資前米度生物企業價值估值為不高於2億元,投資後估值為不高於2.1億元。
米度生物成立於2012年11月29日,註冊資本1965.2357萬,法定代表人李新平。米度生物是國內最早成立的以分子影像技術為特色的醫藥研發CRO科技服務企業,針對放射性藥物提供從早期開發、CMC、臨牀前、臨牀及註冊申報的一站式服務。米度生物目前股權結構為世康控股持有48.31%股權,南京米安北持有35.07%股權,及南京雲米持有16.62%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.